Business
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025
Net sales increased 30% year-over-year to $129.4 million in 2025 Gross margin increased 250 bps year-over-year to 64.3% in 2025 Net income increased 103%
About this update from Niagen Bioscience, Inc.
[{"type":"text","content":"\nNet sales increased 30% year-over-year to $129.4 million in 2025\nGross margin increased 250 bps year-over-year to 64.3% in 2025\nNet income increased 103% year-over-year to $17.4 million in 2025\nAdjusted EBITDA increased 139% year-over-year to $20.4 million in 2025\nCash and cash equivalents totaled $64.8 million at December 31, 2025 compared to $44.7 million at December 31, 2024\nFull year 2026 net sales outlook reflects between 10-15% growth, excluding the recently sold reference standards segment\n\n\n LOS ANGELES--(BUSINESS WIRE)--\nNiagen Bioscience, Inc. (NASDAQ:NAGE) today announced its fourth quarter and fiscal year 2025 financial results.\n\n\nFourth Quarter 2025 Financial Highlights Compared to Prior Year Quarter\n\n\n\nTotal net sales increased 16% to $33.8 million, with Tru Niagen® sales of $27.5 million, up 21% from the prior year quarter.\n\n\n\nGross margin increased 160 basis points to 64.1%.\n\n\n\nNet income of $4.1 million compared to $7.2 million in the prior year quarter. Q4 2024 benefited from a $3.5 million reversal of previously accrued royalties and license maintenance fees, and a $1.3 million recovery of credit losses related to the Elysium Health settlement, while the current-year quarter benefited from a $2.0 million gain related to the settlement of royalty obligations.\n\n\n\nBasic earnings per share was $0.05, and diluted earnings per share was $0.05, compared to $0.09 earnings per share in the prior year quarter for each.\n\n\n\nAdjusted EBITDA, a non-GAAP measure, was $4.1 million, an increase of $0.7 million from the prior year quarter.\n\n\n\nFull Year 2025 Financial Highlights Compared to Prior Year\n\n\n\nDelivered on latest financial outlook across key metrics, demonstrating strong operational execution and focus on delivering shareholder value.\n\n\n\nTotal net sales increased 30% to $129.4 million, with Tru Niagen® sales of $97.7 million and Niagen ingredient sales of $27.9 million, up 27% and 45%, respectively.\n\n\n\nGross margin increased 250 basis points to 64.3%.\n\n\n\nSelling and marketing expense improved 220 basis points as a percentage of net sales to 27.4%, reflecting increased operating leverage.\n\n\n\nNet income of $17.4 million, an increase of $8.8 million from $8.6 million in the prior year. The prior year included a $3.5 million reversal of previously accrued royalties...